17/05/2024 - 11:00

PharmAust receives FDA approval

17/05/2024 - 11:00

Bookmark

Save articles for future reference.

Shares in Claremont-based PharmAust rose 5 per cent early on Friday morning, following news the company had received orphan drug designation for both monepantel and the treatment of motor neurone disease and amyotrophic lateral sclerosis.

Subscribe to read this article.

Register or login now and receive unlimited access to our award-winning, unbiased and trusted
journalism. Your key to local business, news, insights and data.

Subscribe today for award-winning, unbiased and trusted journalism

Subscription Options